HUP0202993A3 - Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxyphenyl)ethyl)]-n-methylamino]-propylamino]-3-(2h)-pyridazinone for producing pharmaceutical compositions having metabolic modulator effect - Google Patents

Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxyphenyl)ethyl)]-n-methylamino]-propylamino]-3-(2h)-pyridazinone for producing pharmaceutical compositions having metabolic modulator effect

Info

Publication number
HUP0202993A3
HUP0202993A3 HU0202993A HUP0202993A HUP0202993A3 HU P0202993 A3 HUP0202993 A3 HU P0202993A3 HU 0202993 A HU0202993 A HU 0202993A HU P0202993 A HUP0202993 A HU P0202993A HU P0202993 A3 HUP0202993 A3 HU P0202993A3
Authority
HU
Hungary
Prior art keywords
pyridazinone
propylamino
dimethoxyphenyl
methylamino
chloro
Prior art date
Application number
HU0202993A
Other languages
Hungarian (hu)
Original Assignee
Egis Gyogyszergyar Nyilvanosan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyogyszergyar Nyilvanosan filed Critical Egis Gyogyszergyar Nyilvanosan
Priority to HU0202993A priority Critical patent/HU227181B1/en
Publication of HU0202993D0 publication Critical patent/HU0202993D0/hu
Priority to PCT/HU2002/000172 priority patent/WO2004024158A1/en
Priority to AU2002356352A priority patent/AU2002356352A1/en
Publication of HUP0202993A2 publication Critical patent/HUP0202993A2/en
Publication of HUP0202993A3 publication Critical patent/HUP0202993A3/en
Publication of HU227181B1 publication Critical patent/HU227181B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU0202993A 2002-09-11 2002-09-11 Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxyphenyl)ethyl)]-n-methylamino]-propylamino]-3-(2h)-pyridazinone for producing pharmaceutical compositions having metabolic modulator effect HU227181B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
HU0202993A HU227181B1 (en) 2002-09-11 2002-09-11 Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxyphenyl)ethyl)]-n-methylamino]-propylamino]-3-(2h)-pyridazinone for producing pharmaceutical compositions having metabolic modulator effect
PCT/HU2002/000172 WO2004024158A1 (en) 2002-09-11 2002-12-28 Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxy-phenyl)-ethyl]-n-methylamino]-propylamino]-3-(2h)-pyridazinone as metabolic modulator
AU2002356352A AU2002356352A1 (en) 2002-09-11 2002-12-28 Use of 5-chloro-4-(3-(n-(2-(3,4-dimethoxy-phenyl)-ethyl)-n-methylamino)-propylamino)-3-(2h)-pyridazinone as metabolic modulator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0202993A HU227181B1 (en) 2002-09-11 2002-09-11 Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxyphenyl)ethyl)]-n-methylamino]-propylamino]-3-(2h)-pyridazinone for producing pharmaceutical compositions having metabolic modulator effect

Publications (4)

Publication Number Publication Date
HU0202993D0 HU0202993D0 (en) 2002-11-28
HUP0202993A2 HUP0202993A2 (en) 2004-06-28
HUP0202993A3 true HUP0202993A3 (en) 2004-10-28
HU227181B1 HU227181B1 (en) 2010-09-28

Family

ID=89980763

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202993A HU227181B1 (en) 2002-09-11 2002-09-11 Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxyphenyl)ethyl)]-n-methylamino]-propylamino]-3-(2h)-pyridazinone for producing pharmaceutical compositions having metabolic modulator effect

Country Status (3)

Country Link
AU (1) AU2002356352A1 (en)
HU (1) HU227181B1 (en)
WO (1) WO2004024158A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU214320B (en) * 1991-12-20 1998-03-02 EGIS Gyógyszergyár Rt. Process for producing novel 3(2h)-pyridazinon derivatives and pharmaceutical compositions producing them
HUP0103064A3 (en) * 2001-07-26 2005-06-28 Egis Gyogyszergyar Nyilvanosan Polymorphic form of 5-chloro-4-(3-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino]-propylamino)-3-(2h)-piridazinone fumarate, its use, process for its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
AU2002356352A1 (en) 2004-04-30
WO2004024158A1 (en) 2004-03-25
HU0202993D0 (en) 2002-11-28
HUP0202993A2 (en) 2004-06-28
HU227181B1 (en) 2010-09-28

Similar Documents

Publication Publication Date Title
PT1419151E (en) Chrystals including a malic acid salt of n-[2-(diethylamino)ethyl] -5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl] -2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
JP2003528918A5 (en)
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
NZ511903A (en) Use of alpha-keto enamine derivatives as ingredients
WO2004016578A3 (en) Arylethanolamine beta2-adrenoreceptor agonist compounds
IT1256282B (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A PARTICULAR PHYSICAL FORM OF A DERIVATIVE OF A HETEROCYCLIC STARCH
CA2556944A1 (en) Thiazole derivative
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
IL176547A0 (en) 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
AP2005003220A0 (en) Novel polymorph of N-Methyl-N-(3-{3-[2-Thienylcarbonyl]-Pyrazol-[1,5-Alpha]-Pyrimidin-7-YI}Phenyl) Acetanide and compositions and methods related thereto.
CA2276429A1 (en) Compositions for the treatment of ards or irds containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide and lung surfactant
HUP0003931A2 (en) Vitronectin receptor antagonist and pharmaceutical compositions containing the compounds
HUP0202993A3 (en) Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxyphenyl)ethyl)]-n-methylamino]-propylamino]-3-(2h)-pyridazinone for producing pharmaceutical compositions having metabolic modulator effect
TR200503401T1 (en) Quetiapine new polymorphs of Fumarate
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
FR2848780B1 (en) USE OF A POWDER ACARICIDE
DK0833626T3 (en) Mono- and disulfo-substituted anthraquions and their use in the treatment of bone matrix disorders
FR2840530B1 (en) COSMETIC COMPOSITION COMPRISING AN AGENT INDUCING THE EXPRESSION OF DOPACHROME TAUTOMERASE (TRP-2) FOR COMBATING CANITIS
YU7604A (en) Polymorph salt of a pyridazinone derivative for the treatment of arrythmia
BR0214780A (en) Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof
BR9815967A (en) Process for the preparation of a 3-substituted 3 (2h) -pyridazinone-4-substituted amino-5-chloro derivative
HU0500684D0 (en) Use of 5-chloro-4-[3-[n-[2-(3,4-dimethoxyphenyl-ethyl)]-n-methylamino]-propylamino]-3-(2h)pyridazinone as acetylcholine dependent potassium channel inhibitor
EP1263435A4 (en) Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
NZ543709A (en) Use of tyrosine kinase inhibitor to treat diabetes
HU0002147D0 (en) Process of ntc-2000 code-number for producing compounds having antiplasmid activity and pharmaceutical compositions containind them

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZV, HU

Free format text: FORMER OWNER(S): EGIS GYOGYSZERGYAR RT., HU

MM4A Lapse of definitive patent protection due to non-payment of fees